Improving physician adherence in heart failure treatment
A Prospective Open Randomised Trial to Test the Efficacy of an Assisted Therapy
This study is testing a new support program to help doctors follow heart failure treatment guidelines better, to see if it can improve patients' health and reduce hospital visits.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 234 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University Innsbruck Academic / other |
| Locations | 2 sites (Graz, Styria and 1 other locations) |
| Trial ID | NCT06714344 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of an Assisted Therapy Optimizing Module designed to enhance physician adherence to guideline-directed medical therapy (GDMT) for heart failure patients. It is a prospective, randomized, multi-sectoral, multi-centre study with a parallel group design. The intervention aims to support network physicians in implementing GDMT, which is often underutilized, particularly in patients enrolled in the telemedicine-supported Herzmobil Tirol program. By improving adherence to GDMT, the study seeks to enhance patient outcomes, including quality of life and reduced hospitalizations.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been hospitalized for decompensated heart failure and require intravenous diuretics.
Not a fit: Patients with multimorbidity, dementia, or those unwilling to participate may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the management of heart failure, leading to better patient outcomes and reduced hospitalizations.
How similar studies have performed: Other studies have shown success in improving adherence to treatment guidelines in chronic conditions, suggesting potential for this approach in heart failure management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: AMPEL, CIP, Version: 1.2 Date: 27.03.2024 1. Written, signed and dated informed consent for inclusion in the HM programme 2. Male and female patients over 18 years of age. 3. Hospitalised for decompensated heart failure requiring intravenous diuretics 4. Need for iv diuresis in nonhospital setting because of impending hospitalization for cardiac decompensation Exclusion Criteria: 1. Multimorbidity (Charlson Comorbidity Index \> 6) 2. Dementia 3. Lack of willingness to participate
Where this trial is running
Graz, Styria and 1 other locations
- Medical University of Graz, University Hospital for Internal Medicine (Cardiology) — Graz, Styria, Austria (Recruiting)
- Medical University of Innsbruck, University Hospital for Internal Medicine III (Cardiology and Angiology) — Innsbruck, Tyrol, Austria (Recruiting)
Study contacts
- Study coordinator: Gerhard Poelzl, Prof. Dr.
- Email: gerhard.poelzl@tirol-kliniken.at
- Phone: +43 (0)50 504-25621
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.